Ranbaxy gets supplier quality award

PTI Aug 25, 2005, 03.59pm IST

MUMBAI: Ranbaxy Laboratories Ltd on thursday said its US subsidiary Ranbaxy Pharmaceuticals
Inc(RPI) has received the Supplier Quality Award from Cardinal Health, the second largest wholesaler in
US.The award has been conferred to the company for its services that supported the Cardinal Health
pharmaceutical distribution for the period July 2004 to June 2005, Ranbaxy informed the Bombay Stock
Exchange.Earlier in June this year, RPI had also received the Supplier Award from Wal-Mart, the largest
chain store in the US, for outstanding performance in the first quarter of 2005, it said.
"We are, delighted to receive our first Supplier Quality Award from Cardinal Health Pharmaceutical
Distribution. The recognition reflects the team's hard work, dedication and joint effort," said Bill Winter,
Executive Director of Sales, RPI.Ranbaxy Pharmaceuticals Inc (RPI) based in Florida, USA, is a wholly
owned subsidiary of Ranbaxy Laboratories and is engaged in the sale and distribution of generic and
branded prescription products in the US healthcare system.

Ranbaxy partners with Validus to sell calcium drug in

US
PTI Sep 3, 2009, 03.05pm IST

NEW DELHI: Ranbaxy Laboratories on Thursday said it has entered into an agreement with the USbased Validus Pharma for selling low cost versions of its calcium drug Rocaltrol.
The company's US-based subsidiary Ranbaxy Pharmaceuticals Inc (RPI) and Validus Pharmaceuticals
LLC have entered into an agreement for marketing and distribution of a generic version of Rocaltrol
(calcitriol), Gurgaon-based Ranbaxy Lab said in a statement.Under the agreement, Rambaxy would
market and distribute an authorized generic version of Rocaltrol in both softgel capsules and an oral liquid
formulation.According to industry estimate, overall market sales for calcitriol softgel capsules and oral
liquid is about USD 70 million.Ranbaxy will launch the product immediately in the United States and
expects to be the only generic company offering all forms and strengths of generic Rocaltrol."Ranbaxy
was very pleased to be selected by Validus as their distribution partner for an authorized generic version
of Rocaltrol," RPI's Sales and Distribution Vice-President Jim Meehan said. We look forward to a long and
prosperous partnership with Validus, Meehan added.Rocaltrol is the brand name for a synthetic form of
calcitriol, a metabolite of vitamin D, which occurs naturally in the human body.

Ranbaxy Laboratories launches generic Cadeut in the

American market
PTI Dec 6, 2011, 05.31pm IST

Tags:

Ranbaxy Laboratories|
Pfizer Inc .|
Caduet

NEW DELHI: Drug firm Ranbaxy Laboratories on Tuesday launched a generic version of Caduet, used for
treating cardio vascular diseases, in the US market, as part of an agreement with Pfizer Inc.
The company's wholly-owned subsidiary Ranbaxy Pharmaceuticals Inc has launched
generic Caduetindicated for patients suffering from both high-blood pressure and high levels of
cholesterol, Ranbaxy said in a statement.he Gurgaon-based firm, however, did not disclose the terms of
the agreement with Pfizer.
Ranbaxy Senior Vice President and Regional Director Americas Venkat Krishnan said: "AtorvastatinAmlodipine besylate tablet is a significant and important addition to our portfolio of cardio-vascular
products, in the US."
Caduet presently marketed by Pfizer is a fixed-dose combination of Atorvastatin-Amlodipine besylate
which also contains a crystalline form of Atorvastatin, Ranbaxy said.
According to IMS-MAT September 2011, Caduet generated total annual sales of USD 339 million in the
US, it added.
The company is making available the full range of the generic version of Caduet, the company said.
Ranbaxy Laboratories, last week launched a generic version of blockbuster cholesterol-lowering drug
Lipitor, which is also a Pfizer brand, in the US market.
Ranbaxy, a part of the Daiichi Sankyo Group, has presence in 125 countries with operations in 46
countries.

Ranbaxy plans to re-launch skincare brand Sotret in

US
Khomba Singh, ET Bureau May 21, 2012, 02.45AM IST

Tags:

US Food and Drug Administration|

united states|
Ranbaxy Laboratories|
Cipher Pharmaceuticals Ltd.

NEW DELHI: India's largest drug maker Ranbaxy Laboratories plans to re-launch its former flagship
skincare brand Sotret in the US, that has been banned for almost four years, through a marketing
partnership with a Canadian firm Cipher Pharmaceuticals Ltd.
"Pre-commercial activities are underway with Ranbaxy Pharmaceuticals, the company's US partner, for a
possible launch (of CIP isotretinoin, chemical name of Sotret) in Q4, 2012," Cipher Inc said in its quarterly
result report earlier this month.
The US drug regulator will have a final review of the drug on May 29, it said. Cipher specialises in
developing improved formulations of existing drugs and out-licenses them to partners for a fee. CIP
isotretinoin is a new formulation and will be manufactured by Cipher, its CEO Larry Andrews told ET.

"The plan is to re-launch Sotret, our flagship product in this segment (dermatology), at the earliest,"
Ranbaxy's CEO and MD Arun Sawhney said in its latest annual report, without specifying details. He said
the launch was part of the Gurgaon-based company's strategy to focus on dermatology to strengthen its
presence in the branded business.
Before a ban in 2008, Sotret was Ranbaxy's third best selling drug globally and was estimated to have
generated over $50 million in annual sales. In September 2008, US Food and Drug Administration (FDA)
banned 30 drugs, including Sotret, made at the firm's two Indian plants for violating US drug
manufacturing norms.
According to US-based Zacks Small-Cap Research, a research firm that tracks small companies,
Ranbaxy is the exclusive partner to market and distribute the drug in the US. The company partly funded
the drug's safety studies and will also pay royalty in mid-teens on net sales of the drug to the Canadian
firm. Ranbaxy declined to comment on a query seeking details about the launch and whether the
company plans to launch its drug independently.
Among the 30 banned drugs, some were yet to be launched at the time of ban. Ranbaxy managed to
launch most of the key ones, notably atorvastatin, the world's best selling drug, by transferring the
marketing application and production of the drug to its American plant in New Jersey. Sotret is possibly
the first drug that was pulled off from the market, which the company is planning to relaunch.
FDA had allowed Ranbaxy to sell those batches of Sotret that were already in the market, but the
company had to withdraw even those in 2009 after the drug failed a stability test.

Ranbaxy Laboratories
From Wikipedia, the free encyclopedia

Ranbaxy Laboratories Limited

Type

Public

Traded as

BSE: 500359
NSE: RANBAXY

Industry

Pharmaceuticals

Fate

Takeover by Daiichi Sankyo

Founded

1961

Headquarter Gurgaon, Haryana, India

s

9976.9 crore (US$1.6 billion)(2011)[1]

Revenue

Net income

EBITDA 1829.9 crore(US$290 million)(2011)

Employees

10,435[1]

Parent

Daiichi Sankyo

Website

www.ranbaxy.com

Ranbaxy Laboratories Limited (BSE: 500359) is an Indian multinational pharmaceutical company that was
incorporated in India in 1961. The company went public in 1973 and Japanese pharmaceutical
company Daiichi Sankyo acquired a controlling share in 2008.[2] Ranbaxy exports its products to 125 countries
with ground operations in 43 and manufacturing facilities in eight countries. [3] In 2011, Ranbaxy Global
Consumer Health Care received the OTC Company of the year award.
Contents
[hide]

1 History

1.1 Formation

1.2 Trading

1.3 Issues

1.4 Acquisition

2 See also

3 Notes

4 External links

History[edit source | editbeta]

Formation[edit source | editbeta]
Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese
company Shionogi. The name Ranbaxy is a portmanteau of the names of its first owners Ranbir and Gurbax.
Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir and Gurbax. After Bhai Mohan Singh's
son Parvinder Singh joined the company in 1967, the company saw an increase in scale.

Trading[edit source | editbeta]

In 1998, Ranbaxy entered the United States, the world's largest pharmaceuticals market and now the biggest
market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005. [citation needed]
For the twelve months ending on 31st December 2005, the company's global sales were at US$1,178 million
with overseas markets accounting for 75% of global sales (USA: 28%, Europe: 17%,Brazil, Russia, and China:
29%). For the twelve months ending on 31st December 2006, the company's global sales were at US$1,300
million.
Most of Ranbaxy's products are manufactured under licence from foreign pharmaceutical developers, though a
significant percentage of their products are off-patent drugs that are manufactured and distributed without
licensing from the original manufacturer because the patents on such drugs have expired.
In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version
of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion. [4] In June 2008,
Ranbaxy settled the patent dispute with Pfizer allowing them to sell Atorvastatin Calcium, the generic version of
Lipitor and Atorvastatin Calcium-Amylodipine Besylate, the generic version of Pfizer's Caduet in the US starting
on the 30th November 2011. The settlement also resolved several other disputes in other countries. [citation needed]
On 23rd June 2006, Ranbaxy received from the United States Food & Drug Administration a 180-day
exclusivity period to sell simvastatin (Zocor) in the US as a generic drug at 80 mg strength. Ranbaxy competes
with the maker of brand-name Zocor, Merck & Co.; IVAX Corporation (which was acquired by and merged into
Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80 mg; and Dr.
Reddy's Laboratories, also from India, whose authorised generic version (licensed by Merck) is exempt from
exclusivity.

In June 2008, Japan's Daiichi Sankyo Company took a majority (50.1%) stake in Ranbaxy, with a deal valued
at about US$4.6 billion. Ranbaxy's Malvinder Singh remained as CEO after the transaction.[5]
On 1st December 2011, Ranbaxy got the much-awaited approval from the US Food and Drug Administration to
launch the generic version of drug lipitor in the United States of America after its patent expired.[6][7]

Issues[edit source | editbeta]

During 2004-2005, Dinesh Thakur and Rajinder Kumar, two Indian employees of Ranbaxy, blew the whistle on
Ranbaxy's fabrication of drug test reports. Thakur's office computer was soon found tampered with. Ranbaxy
then accused Thakur of visiting graphic websites using his office computer, forcing him to resign in 2005.
Thakur escaped from India to the USA and contacted the Food and Drug Administration which started
investigating his claims.[8]
As a result, on 16th September 2008, the Food and Drug Administration issued two Warning Letters to
Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two manufacturing plants in India.
[9]

By 25th February 2009 the US Food and Drug Administration said it halted reviews of all drug applications

including data developed at Ranbaxy's Paonta Sahib plant in India because of a practice of falsified data and
test results in approved and pending drug applications.[10]
On 8th February 2012, three batches of the gastric acid secretion inhibitor Pantoprazole (PPI-Inhibitor) were
recalled in The Netherlands due to the presence of impurities. [11]
On 9th November 2012, Ranbaxy halted production and recalled forty-one lots of atorvastatin due to glass
particles being found in some bottles.[12][13]
In May 2013 the US fined the company US$500 million after found guilty of misrepresenting clinical generic
drug data and selling adulterated drugs to the United States. [14]
Ranbaxy is among the leading manufacturer of generic medicines in India along with it peers Sun
Pharmaceutical , Lupin and Aurbindo Pharma.

Acquisition[edit source | editbeta]

In June 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy,[15][16] for a value $2.4 billion. In November
2008, Daiichi-Sankyo completed the takeover of the company from the founding Singh family in a deal worth
$4.6 billion[17] by acquiring a 63.92% stake in Ranbaxy.

The addition of Ranbaxy Laboratories extends Daiichi-Sankyo's operations - already comprising businesses in
22 countries.[citation needed] The combined company is worth about US$30 billion.[18]
In 2009 it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the India operations
of Ranbaxy Laboratories.[19][20]

Ranbaxy gains 34%: Five reasons why the stock was

on a high
ECONOMICTIMES.COM Aug 8, 2013, 05.00PM IST

Tags:

united states|
Sun Pharma|
stocks|
Shares|
Ranbaxy Laboratories|
Market|
Malaysia|
FDA|
earnings|
BSE|
Bombay stock exchange|
Africa

(The surge comes on a day when)

NEW DELHI: Shares of Ranbaxy rallied 34 per cent in intraday trade on the BSE on Thursday, a day
when Malaysia allocated RMSB, its joint venture with Malaysian shareholders, space for setting up
a greenfieldmanufacturing unit; and also a day after the company reported earnings for the second
quarter of the calendar year 2013.

The pharma major finally ended 27.49 per cent higher at Rs 359.40, from Wednesday's closing price of
Rs 281.90. It hit a low of Rs 279 and a high of Rs 377.70 in the intraday trade on the Bombay Stock
Exchange (BSE).
Ranbaxy Labs posted a consolidated net loss of Rs 524.24 crore for the quarter ended June 30, 2013,
mainly on account of foreign exchange losses and goodwill impairment in its operations in France.
However, analysts at most brokerage firms are of the view that Ranbaxy is a 'good' buy with a limited risk
given the fact the stock has already corrected a lot so far in 2013.
We have collated top five reasons which could have aided the sharp rise in the stock price of Ranbaxy in
today's trade:
NOD FOR MANUFACTURING FACILITY IN MALAYSIA
Ranbaxy Laboratories said that Ranbaxy Malaysia Sdn Bhd (RMSB), its joint venture with Malaysian
shareholders, has been allocated site for setting up a greenfield manufacturing facility in Malaysia.
The JV company signed a 'letter of offer' agreement with Kulim Hi Tech Park (KHTP), a wholly owned
state agency and industrial park that houses various other leading industries located at Kulim, Ranbaxy
Laboratories said.
Ranbaxy Laboratories holds a 71 per cent stake in the joint venture RMSB.
MARGIN IMPROVEMENT
With strong operating performance and sales especially in US showing some sort of uptick in the base
business is a positive sign for the pharma major, say analysts.
Core OPM picked up sharply at 9.8 per cent as compared to 7.6 per cent reported in 1Q. The
management expects to scale up margins in coming quarters led by led by market share gains on
Isotretinoin (from c. 14%), Africa+India biz recovery and strengthening manufacturing processes.
"Management guides gradual recovery in base margins, QoQ pick up in contractual payment from one
time DOJ settlement related expense (non-recurring), step down of consent decree expense from
1QC14," Sbicap Securities said in a report.
ROBUST US SALES IN THE QUARTER
"With healthy market share in generic Actos and Evoxac, along with scale up in Absorica, Ranbaxy's base
business is strengthening," Elara Securities said in a report.
The company remains confident of monetizing generic Diovan and Valcyte (expecting launch in
September 2013) this year. The company paid out US$ 500mn to the US FDA and DoJ during the
quarter," added the report.

US quarter run rate have further improved to $138mn from $110mn QoQ, led by MS gains in Absorica
(14% vs. 10% qoq).
"Further traction in Absorica along with potential launches in Diovan (4QC13), Valcyte (4QC13) and
Nexium (2QC14) expects to result in $626/$922mn in Sales for C13/14e," say analysts.
STOCK WAS HIGHLY OVERSOLD AHEAD OF RESULTS
Shares of Ranbaxy Laboratories came under pressure earlier in the year after the drug maker pleaded
guilty to US felony charges related to drug safety and agreed to pay $500 million in settlement.
Ranbaxy Laboratories has plunged over 40 per cent so far in the year 2013 (as of data collected on
August 7) largely on account of USFDA concerns.
"My sense is Ranbaxy is the next Sun Pharma or the next big story in the pharma space that is emerging,
and if somebody has a patience I would look at it with a potential to be into the Rs 1000 category in
probably about 18 months' time," said Prakash Diwan, Director, Altamount Capital Management in an
interview with ET Now.
"We need to have some patience but it is finally good time as next set of earnings will not only show some
growth in top line but it will also shows some new products getting accepted in a significant way for the
company," he added.
BROKERAGE VIEWS
Analysts at most brokerage firms are of the view that Ranbaxy is a 'good' buy with a limited risk given the
fact the stock has already corrected a lot so far in 2013.
As much as six global brokerage houses have 'buy' or an 'overweight' rating on Ranbaxy Laboratories
post the Q2 results, but most of them have also revised their target price downwards.
With strong operating performance and sales especially in US showing some sort of uptick in the base
business is a positive sign for the pharma major, say analysts.

Ads by Google

Ranbaxy spurts 34% as Malaysia allots site for

manufacturing unit
ECONOMICTIMES.COM Aug 8, 2013, 03.30PM IST

Tags:

united states|
Shares|
Ranbaxy Laboratories|
Pharma|
markets|
France|
earnings

(Most brokerage firms are)

NEW DELHI: Shares of drug major Ranbaxy Laboratoriessaw a sudden spurt in intraday trade, rising as
much as 15% on the NSE, and a little below that level on the BSE, as its joint venture with Malaysian
shareholders - Ranbaxy Malaysia Sdn Bhd (RMSB) - was allocated site for setting up a greenfield
manufacturing facility in Malaysia.
The stock rallied as much as 34 per cent in afternoon trade on the BSE to touch its intraday high of Rs
377.70.
On Wednesday, Ranbaxy Labs posted a consolidated net loss of Rs 524.24 crore for the quarter ended
June 30, mainly on account of foreign exchange losses and goodwill impairment in its operations
in France. However, analysts at most brokerage firms are of the view that Ranbaxy is a 'good' buy with a
limited risk given the fact the stock has already corrected a lot so far in 2013.
Shares of Ranbaxy Laboratories came under pressure earlier in the year after the drug maker pleaded
guilty to U.S. felony charges related to drug safety and agreed to pay $500 million in settlement.
Ranbaxy Laboratories has plunged over 40 per cent so far in the year 2013 (as of data collected on
August 7) largely on account of USFDA concerns.
As much as six global brokerage houses have 'buy' or an 'overweight' rating on Ranbaxy Laboratories
post the Q2 results, but most of them have also revised their target price downwards.
The company's CEO said in an analyst on Wednesday said that during the quarter, 16 national regulatory
agencies have inspected various facilities of the company.
With strong operating performance and sales especially in US showing some sort of uptick in the base
business is a positive sign for the pharma major, say analysts.

The net sales came in at Rs 2,663.3 crore a decline of 17.8 per cent in sales. This was much lower than
expectation of Rs 2,850cr during 2QCY2013.However, excluding the exclusivities - the base business
clocked a double digit growth during the period.
"The growth was mainly lead by the branded business Emerging business of LATAM and branded
business of Africa, APAC and Russia Indian sales during the period came in flat, on back of the new drug
policy," Sarabjit Kour Nangra, VP-Research, Pharma at Angel Broking.
"On back of attractive valuations, we maintain our buy on the stock," added Nangra.
Ranbaxy CEO & managing director Arun Sawhney said in an analyst call on Wednesday evening that
absolute sales were lower because in the corresponding quarter last year the sales included contribution
from 180 days marketing exclusivity opportunities in the US market.
Ads by Google

Dental Implants SurgeryDental Implants at Affordable Price

Lifetime Warranty. MDS Dentist.www.signaturesmiles.in

Aviva i-Life Term PlanPay Only Rs.16*/day and Get 1 Crore Life
Cover+ Tax Benefits. Buy Now!www.avivaindia.com/Term-Plan
"Growth levers remains intact for Ranbaxy as operating leverage through product approvals or facility
utilisation, near-term FTF monetization (Diovan, Valcyte) and market share pick up in the branded derma
portfolio will all lead to margin expansion," Sbicap Securities said in a note.
"We expect base biz valuation to unlock over with clarity emerging towards resumption US supplies from
Dewas," added the report.
Sbicap is of the view that the US quarter run rates have further improved to $138mn from $110 mn
reported in the previous quarter, led by MS gains in Absorica (14% vs. 10% qoq).
We have collated recommendations from various brokerage firms on 12-months target price of
Ranbaxy post Q2 results:-

Ads by Google

Despite regulatory issues, Ranbaxy Laboratories

remains a high-risk, high-return stock
Narendra Nathan, ET Bureau Aug 12, 2013, 08.00AM IST

Tags:

US FDA|
stocks|
Ranbaxy Laboratories|
Ranbaxy|
Paonta Sahib|
North America|
ET Wealth|
Drugs Price Control Order|
Abbreviated New Drug Application

(Despite good results, the)

The analyst community is taking a bullish stand onRanbaxy Laboratories despite a fall in net sales and
EBITDA in the second quarter of 2013, because the quarterly numbers were better than the street
expectations. During this period, the 9.8 per cent adjusted EBITDA margin was much higher compared
with the expected value of 8 per cent, and the first quarter value of 6.4 per cent.
The improving visibility about the company's prospects is another reason for this sudden turnaround in
sentiments. The company's sales from North America rose 23.6 per cent on a quarter-over-quarter basis
despite its ongoing problems with the US Food and Drug Administration (FDA). Ranbaxy's operating
margins are at very low levels compared to its peers, primarily because of the continuing expenses to
improve its Dewas and Paonta Sahib facilities to comply with the US FDA's consent decree.

However, these expenses are expected to taper off

after 2014. This means that the margin improvement is inevitable in the next two years, when all the US
FDA issues are resolved. Once this happens, the US sales will receive a major boost and Ranbaxy will
start getting ANDA ( Abbreviated New Drug Application) approvals from the FDA. The DPCO ( Drugs
Price Control Order) is another issue that the company has to grapple with and its domestic sales
remained flat in the second quarter due to this.
Though the compulsory reduction of essential drug prices will affect the entire pharma industry, the
Ranbaxy management has indicated an 8 per cent impact on its domestic business due to this. The issue
may get resolved after the 2014 general elections.
Since Ranbaxy Laboratories is still grappling with the US FDA and DPCO issue, it is a high-risk, highreturn bet and, therefore, investors with a moderate risk appetite can consider this counter for parking
their long-term money.
Its valuation has also reached the desired level due to continuous underperformance as is evident from
the relative performance chart. However, the massive short-covering after the better-than-expected
second quarter numbers reduced this gap from 59 per cent to 37 per cent one week earlier. So, investors
need to wait for a correction in this stock to enter it.

Selection methodology:
We pick the stock that has shown the maximum increase in consensus analyst rating during the past
month. Consensus rating is arrived at by averaging all analyst recommendations after attributing
weightages to each of them (5 for strong buy, 4 for buy, 3 for hold, 2 for sell and 1 for strong sell) and any
improvement in the rating indicates that the analysts are becoming more bullish on the stock.
To ensure that we pick only those companies that have a decent analyst coverage, this search is
restricted to stocks that have been covered by at least 10 analysts.

Ads by Google

Why Ranbaxy is up over 35% after posting Q2 loss

NDTV | Updated On: August 08, 2013 15:27 (IST)

Ranbaxy shares jumped over 35 per cent to Rs. 380 on Thursday, a day after India's top
drugmaker (by sales) reported a net loss of Rs.524 crore for the June quarter. Ranbaxy was
the top gainer on the 50-share Nifty benchmark.
Here's why the stock is up today:
1.

Strong growth in U.S.: Ranbaxy's dollar revenues were encouraging,

with the U.S. business reporting a 25 per cent sequential growth. U.S. is the
biggest drug market for Ranbaxy. Global investment bank Macquarie said U.S.
sales were driven by the newly launched acne treatment drug Absorica, which
could see much higher sales in future. Macquarie has an "outperform" rating on
Ranbaxy.

2.

Operationally strong: Ranbaxy posted a loss of Rs. 524 crore in the June
quarter, but these losses were not related to Ranbaxy's core business. Ranbaxy
operates in a number of countries and generates revenue in different currencies.
The company said it incurred forex loss of Rs. 540 crore in the June quarter. It
wrote off another Rs. 120 crore in loss of goodwill at its overseas subsidiaries.
Negative publicity about a firm can create goodwill impairment, as can the
reduction of brand-name recognition. Ranbaxy has been in news for all the
wrong reasons - its factories have been banned by the US regulator, it has been
pulled up by the European Union and the company has been dragged into
litigation in India -- recently.

3.

Sales in line: Ranbaxy posed a 17 per cent year-on-year drop in sales

at Rs.2,633 crore. However, revenues were in line with Street estimates. Stocks
tend to react positively if operational numbers like sales and profit beat or meet
analyst estimates.

4.

Margins surprise: Ranbaxy's gross margins rose sequentially, beating

estimates. EBITDA (Earnings before interest, tax, depreciation and amortization)
margins, a key indicator of profitability, rose 450 basis points sequentially.
Ranbaxy's management guided for margin recovery over next 18-24 months.

5.

Ranbaxy attractive bet after recent fall: Ranbaxy shares have fallen
sharply since the drugmaker decided to pay $500 million in civil and criminal
fines under a settlement agreement with the US Department of Justice. The
stock has fallen 30 per cent over the last three months, while the broader BSE
healthcare benchmark, comprising other drugmakers, has remained flat.
Analysts say Ranbaxy shares have become attractive after the sharp fall.

Evidence against Ranbaxy likely to be

furnished in SC
CNN-IBN | Posted on Aug 12, 2013 at 09:00am IST
Share

Is Jesus Really God?

Discover the Evidence From Scholars About Jesus' Claims to be God Y-Jesus.com
Ads by Google

New Delhi: Evidence in a case against Ranbaxy is likely to be furnished in the Supreme Court on
Monday. Earlier in August, the Supreme Court while replying to a petition seeking cancellation of
Ranbaxy's manufacturing licence had said that the petitioner can file the documents to prove that the
company sold adulterated drugs.
The Supreme Court had on June 25 dismissed a PIL which had alleged that Ranbaxy manufactured
and sold adulterated drugs. The court in its order said that there is no evidence to show that the
pharma giant manufactured substandard drugs. The apex court also said that the petitioner failed to
bring in evidence against Ranbaxy.
The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug.
The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling
substandard and adulterated drugs. The pharma giant was asked to pay a fine of 500 million dollars

The Supreme Court had on June 25 dismissed a PIL which had alleged that Ranbaxy manufactured and sold adulterated
drugs.

We offer High Quality, Affordable Pharmaceuticals

We, at Ranbaxy, are committed to providing affordable pharmaceutical products of global quality
standards to patients all over the world. In our manufacturing facilities, approved by various regulatory
bodies in the U.S., Europe, Africa, Asia Pacific and Latin America, we manufacture Generics,
Differentiated products, Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active
Pharmaceutical Ingredients (APIs) and Intermediates.
We manufacture and market over 500 molecules and their combinations in multiple dosage forms,
catering to patient needs in various therapies. These include Anti-infectives, Cardiovascular, Pain
management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology,
Orthopaedics, Nutritionals and Urology. In several countries, Ranbaxy ranks among the leading
companies in these therapy areas.
Our presence in more than 150 countries helps us in being responsive to local treatment needs while
continually improving our global product portfolio.

Our unique hybrid business model, involving synergistic collaboration with Daiichi Sankyo, gives us
access to originator products in various markets around the world. We are among the very few global
pharmaceutical companies that offer a wide range of both generic and innovator products.

Top Products of Ranbaxy

Molecule

Drug Class

Atorvastatin & Combinations

Hypolipidemics

Donepezil

Anti-Alzheimers

Valacyclovir

Anti-Virals

Simvastatin

Hypolipidemics

Amoxicillin+Clavulanic Acid

Anti-bacterials

Ketorolac

Analgesics

Ciprofloxacin & Combinations

Anti-bacterials

Imipenem + Cilastatin

Anti-bacterials

Loratadine & Combinations

Anti-histaminics

Fenofibrate & Combinations

Hypolipidemics

Amoxicillin & Combinations

Anti-bacterials

Cephalexin

Anti-bacterials

Clarithromycin

Anti-bacterials

Ambazone

Oral Antiseptics

Pantoprazole & Combinations

Proton Pump Inhibitor

Therapy Areas

Anti-infectives
having
Read More

We have a significant presence in the Anti-infectives segment

Cardiovascular
due to changing
Read More

Cardiovascular (CVS) ailments are on the rise all over the world

Pain and Musculoskeletal

Musculoskeletal
Read More

Gastrointestinal
us
Read More

Respiratory
to
Read More

Central Nervous System

System (CNS)
Read More

Anti-retrovirals
Read More

Dermatology
markets
Read More

Some of our best-selling molecules in the Pain and

Gastrointestinal is another significant therapeutic segment for

There is a growing global population of patients with ailments relating

We have a wide portfolio of drugs for Central Nervous

We offer a wide range of World Health Organisation (WHO)

We have a major focus in Dermatology with a presence across

Branded Pharmaceuticals Business

Our branded pharmaceuticals business, Ranbaxy Laboratories Inc. (RLI), is committed to developing a
distinguished branded pharmaceutical business. The foundation for establishing the branded business
rests on three strategic pillars:
1.

Licensing/acquisitions

2.

In-house product development

3.

Marketing alliances
We are actively looking to acquire more products in order to augment RLIs product offerings to
customers.
An important factor in the growth of our branded business is product development expertise. We have
highly advanced capabilities in Novel Drug Delivery Systems (NDDS) that offer new and improved
formulations to currently available chemical entities. For example, we have developed a once-daily
formulation of the anti-infective Cipro (ciprofloxacin), which we have licensed to Bayer, the original
marketer of the drug.
We hope to take advantage of our product development expertise by launching our own proprietary
brands, which are currently at various stages of development.
With a well-defined branded product portfolio, we are actively looking for marketing partners with
complementary skills and needs.
Our branded prescription division in the US market will expand and grow through our global R&D
efforts, continued exploration of NDDS; licensing activities; and mergers and acquisitions. Our
commitment to invest significantly in R&D will translate into the development of innovative branded
products with a wide range of therapeutic uses.

Products List of RANBAXY (C V)

ANGISTAT 2.5MG CAPS

ANGISTAT 6.5MG CAPS

CANDESAR 4MG TAB

CANDESAR 8MG TAB

CARDIBETA 100MG TA

CARDIBETA 12.5MG TAB

Products List of RANBAXY

(CHC)
CHERICOF
SOFTGELS

CHERICOF
SYRUP(LARG
E)

CHERICOF
GARLIC
SYRUP(SMAL PEARLS(100`
L)
S)
GARLIC
PEARLS(30`S)

OLESAN OIL

PEPFIZ TAB
2`S (EACH)

PEPFLUX
GEL(GINGER)

PEPFLUX
GEL(LEMON)

REVITAL
CAPS(10`S
PACK)

REVITAL
CAPS(30`S
PACK)

REVITAL
CAPS(60`S
PACK)

REVITAL LIQ

REVITAL
SENIOR TAB
(10`S PACK)

REVITAL
SENIOR TAB
(30`S PACK)

REVITAL
WOMAN TAB
(10`S PACK)

REVITAL
WOMAN TAB
(30`S PACK)

REVITALITE
POWDER

VOLINI
ACTIVE GEL

VOLINI DUO
TAB

VOLINI GEL
VOLINI
SACHET(TUB GEL(LARGEE)
50GM)
VOLINI
VOLINI
GEL(MEDIUM GEL(SMALL-30GM)
15GM)

VOLINI
SPRAY
(LARGE)

VOLINI
SPRAY
(SMALL)

VOLINI TABS
CARDIBETA XR 12.5MG TAB

CARDIBETA XR 25MG TAB

CARDIBETA XR 50MG TAB

CARDIBETA-AM TAB

CARDIBETA-AMF TAB

COVAMLO TAB

COVANCE-25MG TAB(10`S STRIP)

COVANCE-50MG TAB(10`S STRIP)

COVANCE-50MG(CP-30`S PK)

COVANCE-AT TAB

COVANCE-D (CP 30`S PACK)

COVANCE-D TAB(10`S STRIP)

FLOTHIN 40MG/0.4ML(EACH)

Revital
Brand: Ranbaxy | Manufacturer: | COD Available | Dispatched in: 1 - 3 working days
11 Reviews
Description Recommended Products
Hectic lifestyles tend to cause fatigue in today's fast paced time, Revital can keep you healthy to face
all this. Ithelps in providing the body with the right amount of vitamins, minerals and ginseng. Now you
can get through the day with just one capsule a day. Revital not only rejuvenates your low energy
level but it also keeps you fresh and active throughout the day. Loaded with essential vitamins and the
minerals, one capsule is sufficient to meet your daily dose of health and keep you physically active and
mentally alert.

2 variants available. Please select Desired Product Variant(s)

Flavor:NA
SIZE:30 Caps

Rs 270

Bottom of Form
Place Order

Flavor:NA
SIZE:60 Caps

Rs 522

Rs 496
5% off

Place Order

Description
Revital is a daily food supplement that has a balanced combination of vitamins, minerals and ginseng.
Ginseng is an herb commonly used to increase energy and well being. The amount of vitamins and
minerals cover the daily requirements of an individual. It helps in decreasing fatigue, it improves
endurance, tolerance and compatibility during stress, it improves concentration, learning and memory and
it can be taken by both males and females over 12 years of age. Suitable for diabetics as it does not
contain sugar.

Detail
Each capsules contain ginseng extract power which is highly concentrated, standardized ginseng extract,
calcium, phosphorous, vitamin c, ferrous, zinc, nicotinamide, calcium, vitamin e, magnesium, potassium,
vitamin, b2, vitamin b1, vitamin b6, manganese, copper and folic acid.
Features And Benefits

It is beneficial for both men and women.

It increases energy levels of the body.

It provides the body with essential supplements.

It contains important minerals and vitamins.

Supplement Facts

Serving Size 1 Capsule

Amount per Serving

Energy

4.23 kcal

Carbohydrate

0.10g

Protein

0.02g

Fat

0.38g

Vitamin A

2000 IU

Vitamin B1

1mg

Vitamin B2

1.5mg

Vitamin B3

10mg

Vitamin B5

5mg

Vitamin B6

1mg

Vitamin B12

1mcg

Vitamin C

40mg

Vitamin D3

200IU

Vitamin E

5mg

Folic Acid

0.12mg

Calcium

75mg

Phosphorus

58mg

Ferrous Fumarate

17mg

Zinc

10mg

Magnesium

3mg

Pottasium

2mg

% Daily Value

Ranbaxy Garlic Pearls

Brand: Ranbaxy | COD Available | Dispatched in: 1 - 3 working days
1 Reviews
Description
The Ranbaxy Garlic 100 Pearls is a natural supplement for a keeping your heart and digestive system
healthy. This product is pretty useful in dealing high blood pressure and protecting body against
several diseases of the heart like arteriosclerosis. These garlic pearls from Ranbaxy are extremely
popular worldwide and help a great deal in relieving problems such as indigestion and gasbuild up in
stomach and intestines. This supplement also aids in managing cholesterol levels in your body, dealing
with chronic cough and cold problems as well as relieving severe pains in joints.
Size:100 pearls per pack

Rs 90
Flavor:NA
SIZE:100 Pearls
Place Order

Description

It is an ideal supplement for matters related to the heart.

Garlic is a vegetable with excellent medicinal value which has been tapped the most in this
product from Ranbaxy.

Indispensable for people with regular digestive disorders

It is very active and starts functioning as soon as it reaches the digestive system.

Provides immediate relief for person suffering from diseases related to heart, blood pressure,
indigestion, chronic cold and cough

Ingredients
Garlic Oil
Intake:
You are ideally advised to consume two-three pearls twice a day in between two consecutive
meals.
Caution:
It shall be consumed only under medical prescription if there is a case of pregnancy or
illness. You must store them in a cool and dry place away from children and pets.
go to top

Description

It is an ideal supplement for matters related to the heart.

Garlic is a vegetable with excellent medicinal value which has been tapped the most in this
product from Ranbaxy.

Indispensable for people with regular digestive disorders

It is very active and starts functioning as soon as it reaches the digestive system.

Provides immediate relief for person suffering from diseases related to heart, blood pressure,
indigestion, chronic cold and cough

Ingredients
Garlic Oil
Intake:
You are ideally advised to consume two-three pearls twice a day in between two consecutive
meals.
Caution:
It shall be consumed only under medical prescription if there is a case of pregnancy or
illness. You must store them in a cool and dry place away from children and pets.
go to top

Revital Senior

Revital Senior
Brand: Ranbaxy | COD Available | Dispatched in: 1 - 3 working days
3 Reviews
Description Special Offers Recommended Products
Revital Seniors is a specially formulated supplement that is enriched with essential Vitamins,
Calcium, Ginseng and Minerals ideal for promoting an improved health and stamina in old age. It is a
daily health supplement which tackles weariness and fatigue to keep one fresh and active, throughout
the day.

1 variants available. Please select Desired Product Variant(s)

Description
Price

Order

SIZE:30 Caps

Rs 295

Rs 288
2% of
Place Order

Description
Revital for Seniors is a combination of ginseng, vitamins and minerals. Ginseng is a herb which
increases energy levels of the body. It also contains 13 Vitamins and 17 Minerals meant to keep you
healthy and fit even after the age of 50.
Features and Benefits

Contains Ginseng

Improves health and immunity

Has an antioxidant property

Improves stamina

Dosage
Take 1 tablet daily after any meal.

Ranbaxy Revitalite Protein Powder

Ranbaxy Revitalite Protein Powder

Brand: Ranbaxy | COD Available | Dispatched in: 1 - 3 working days
1 Reviews
Description Recommended Products
Ranbaxy Revitalite Protein Powder is a total vegetarian protein supplement that contains no flavour,
sugar or preservatives.

Rs 490

Rs 475
you save 3%
Flavor:NA
SIZE:0.44 lb / 0.2 Kg Jar

Supplement Fact
Serving Size 1 Scoop

Approximate
Composition

Amount per
Serving

10g

% Daily
Value

**

Energy

36Kcal

**

Protein

8g

**

Carbohydrates

0.5

**

Fat Content

0.3g

**

Calcium

70mg

**

Iron

1mg

**

Isoleucine

408mg

**

Sold Out

Description
Ranbaxy Revitalite Protein
Powder is neutral when it comes
to taste and is stable when
cooked. You can easily add it to
any beverage or food of your
choice. Ranbaxy Revitalite
Protein Powder is based on soy
protein isolate that has 90 percent
protein. It offers various benefits
for people of all ages.
Details
Ranbaxy Revitalite Protein
Powder is a great protein
supplement that can be added to
your regular diet.
Features And Benefits

Leucine

696mg

**

It offers immunity and preserves

good health.

Methionine

224mg

**

It helps repair daily wear and

tear of your body.

Phenylalanine

752mg

**

It helps in taking care of the

overall growth and development
of your body.

Threonine

320mg

**

Tryptophan

104mg

**

Valine

432mg

**

Histidine

216mg

**

How to use : You must mix 1 scoop of Ranbaxy

Revitalite Protein Powder to a glass full of water or milk or
your favorite beverage.

Storage Instructions :Always ensure to air-tight the

container properly after opening it. It is advisable to store
the container in a cool and dry place

Servings Per Container